Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Stopped Study was abandoned before opening to accrual. Replaced by another study.

Conditions

• Breast Cancer

Interventions

• DRUG: IGF-1R inhibitor OSI-906
• DRUG: erlotinib hydrochloride
• DRUG: goserelin
• DRUG: letrozole

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

• [object Object]